Return to Main Site 617-919-3019
401 Park Drive, 7th Floor East, Boston, MA 02215

TIDO Technology Search



Invention Type

Diagnostic/Prognostic
Information Technology/Software
Medical Device
Other
Research Tool
Therapeutics

Research Area

Allergy/Respiratory/Pulmonary Disease
Anesthesia
Audiology
Cardiovascular/Cardiology
Degenerative Disease
Dermatology
Endocrinology
Gastrointestinal/Nutrition
Genetic Disease
Health Care Management
Immunology
Infectious Disease
Inflammation
Internal Medicine
Metabolic Disease
Musculoskeletal
Neonatology/Pediatric
Neurology/Neuroscience
Oncology/Hematology
Ophthalmology
Orthopedics
Otolaryngology/Audiology
Pain
Pathology
Personalized Medicine
Psychiatric Disease
Radiology
Regenerative Medicine
Reproduction/Ob-Gyn
Stem Cell
Surgery/Wound Healing
Urology
CMCC 736

Collagen XXIII: A novel biomarker for non-small cell lung cancer and prostate cancer

Inventors: Bruce Zetter, Lere Bao, Jackie Bhisitkul Banyard

Invention Types: Diagnostic/Prognostic

Research Areas: Oncology/Hematology

Keywords: Biomarker

For More Information Contact:  Dietz, Ryan

 

Invention Description:

Collagen XXIII was originally identified by Dr. Bruce Zetter's group as a transmembrane collagen in prostate carcinoma cells in 2003 and was shown to be upregulated in metastatic prostate cancer.|


In 2007, Dr. Zetter's studies detected Collagen XXIII protein at very low levels in benign prostate tissue, whereas a significant increase in Collagen XIII in was seen in prostate cancer. Distant metastases exhibited significantly higher collagen XXIII levels compared with either localized prostate cancer or regional (lymph node) metastases. Patients with high collagen XXIII levels had a 2.8-fold higher risk of Prostate-Specific Antigen (PSA) failure with median time to failure of 8.1 months, compared with low collagen XXIII patients with a median time to failure of 5 years. The presence of collagen XXIII was significantly associated with time to PSA recurrence, independent of other clinical variables. Collagen XXIII was also detected in prostate cancer patient urine, with reduced levels after prostatectomy, indicating potential as a noninvasive fluid biomarker.


In additional studies published in 2010, Dr. Zetter's lab found that collagen XXIII could be used as a tissue and urinary biomarker for NSCLC, in which positivity in tissue or urine significantly correlates with the presence of NSCLC and high staining intensity is a significant recurrence predictor. Dr. Zetter's studies found that Collagen XXIII was present in tissue samples from a variety of cancers. Within lung cancer tissues, collagen XXIII staining was enriched in NSCLC subtypes. Collagen XXIII was present in 294 of 333 (88%) lung adenocarcinomas and 97 of 133 (73%) squamous cell carcinomas.


Moreover, a 2011 study published in Oncogene suggests a potential role for collagen XXIII in mediating metastasis and cancer progression by facilitating cell–cell and cell–matrix adhesion as well as anchorage independent cell growth.

Applications:

These findings suggest that Collagen XXIII could be a marker in cancer, especially prostate cancer and non-small cell lung cancer. Lung cancer is the leading cause of cancer-associated mortality, accounting for over 25% of cancer-related deaths and 15% of new cancer cases annually. Lung cancer is divided into small cell lung cancer (SCLC) and non-SCLC (NSCLC), with prevalence rates of 14% and 85%, respectively. There are approximatively 200,000 new cases of prostate cancer and an estimated 30,000 deaths. A quarter of patients who have undergone radical prostatectomy are likely to develop metastasis within 10 years.

Competitive Advantages:

• Collagen XXIII may be superior to PSA in that it may be able to distinguish between a prostate disease that will progress to morbidity from those that will not

• Use of the Collagen XXIII marker may decrease the number of unnecessary treatment and surgeries for prostate disease

• Collagen XXIII could be used for decision-making/therapy guidance, for early prediction at Stage 1 /2 in tissue, and for treatment effectiveness in urine of patients with NSCLC |

Business Opportunity:

Exclusive License to develop a biomarker diagnostic test

Key Publications: Spivey KA, Chung I, Banyard J, Adini I, Feldman HA and Zetter BR. A role for collagen XXIII in cancer cell adhesion, anchorage-independence and metastasis. Oncogene advance online publication, 3 October 2011. Pubmed PMID:21963851
This paper evaluated by Faculty of 1000 on 25 Nov 2011.


Spivey KA, Banyard J, Solis LM, Wistuba II, Barletta JA, Gandhi L, Feldman HA, Rodig SJ, Chirieac LR, Zetter BR. Collagen XXIII: a potential biomarker for the detection of primary and recurrent non-small cell lung cancer. Cancer Epidemiol Biomarkers Prev. 2010 May;19(5):1362-72. PubMed PMID: 20447926; PubMed Central PMCID: PMC2880394.


Banyard J, Bao L, Hofer MD, Zurakowski D, Spivey KA, Feldman AS, Hutchinson LM, Kuefer R, Rubin MA, Zetter BR. Collagen XXIII expression is associated with prostate cancer recurrence and distant metastases. Clin Cancer Res. 2007 May 1;13(9):2634-42. PubMed PMID: 17473194.||

Banyard J, Bao L, Zetter BR. Type XXIII collagen, a new transmembrane collagen identified in metastatic tumor cells. J Biol Chem. 2003 Jun 6;278(23):20989-94. Epub 2003 Mar 18. PubMed PMID: 12644459.||

IPStatus: Patented